Tesaro v Myr­i­ad: Ni­ra­parib part­ners squared off in court as Tesaro tried to quash a con­trary press re­lease

When Tesaro re­leased their da­ta on the PARP drug ni­ra­parib a few days ago, the biotech was de­ter­mined to make a case for a broad ap­proval, with­out any need for a di­ag­nos­tic test to dis­tin­guish pa­tients with a par­tic­u­lar bio­mark­er for ovar­i­an can­cer.

Not every­body, of course, bought in to that ar­gu­ment, with some crit­ics say­ing that the da­ta were iffy at best. One key ob­jec­tion, though, came from Myr­i­ad Ge­net­ics, which de­vel­oped the com­pan­ion di­ag­nos­tic test Tesaro used in Phase III and now wants to see put in­to use. And Tesaro wound up tak­ing them to court in a failed at­tempt to shut it down.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.